TABLE 1. Clinical presentation of functioning NETs (Jensen et al, 2012 3 and Sara Massironi et al, 2008 16 ).
| Tumor | hormone | Localization | Malignancy (%) | Metastasis (%) | Clinical presentation | men-1# (%) |
| Insulinoma | Insulin | Pancreas (>99%) | <10 | 10 | Episodic Hypoglycemia | 8-10 |
| Gastrinoma | Gastrin | Duodenum (70%) Pancreas (25%) | 60-90 | 60 | Peptic ulcers, diarrhea, GERD* | 30 |
| VIPoma | Vasoactive intestinal peptide (VIP) | Pancreas (90% | 40-70 | 70 | Severe diarrhea, hypokalemia, hypochlorhydrya | Rare |
| Glucagonoma | Glucagon | Pancreas (100%) | 50-80 | 60 | Cutaneous rash, diabetes, weight loss, anemia | Rare |
| Somatostatinoma | Somatostatin | Pancreas (55%) Midgut (44%) | >70 | 84 | Diarrhea, diabetes, gallstone disease, weight loss | Unassociated |
# Multiple Endocrine Neoplasia Type 1; *GERD: Gastroesophageal reflux disease